{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:07:26Z","timestamp":1793984846302,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08123"],"award-info":[{"award-number":["23K08123"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.surg.2025.109864","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:21:31Z","timestamp":1763140891000},"page":"109864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prognostic significance of neoadjuvant gemcitabine and S-1 chemotherapy with or without concurrent radiation in patients with resectable and borderline resectable pancreatic cancer: A post hoc analysis of 2 phase II trials"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3115-9466","authenticated-orcid":false,"given":"Hirofumi","family":"Akita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Tomimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2025.109864_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.surg.2025.109864_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pan.2015.09.008","article-title":"Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study","volume":"15","author":"Matsumoto","year":"2015","journal-title":"Pancreatology"},{"key":"10.1016\/j.surg.2025.109864_bib3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.surg.2025.109864_bib4","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Evans","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2025.109864_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.surg.2025.109864_bib6","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2025.109864_bib7","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2025.109864_bib8","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2025.109864_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with Gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2025.109864_bib10","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2025.109864_bib11","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1245\/s10434-019-07735-8","article-title":"A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma","volume":"26","author":"Eguchi","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109864_bib12","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1245\/s10434-024-15199-8","article-title":"Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015)","volume":"31","author":"Yamada","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109864_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.surg.2025.109864_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2025.109864_bib16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","article-title":"The 2016 update of the International study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after","volume":"161","author":"Bassi","year":"2017","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2025.109864_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.surg.2025.109864_bib18","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jhbp.1353","article-title":"Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)","volume":"30","author":"Sugiura","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.surg.2025.109864_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","article-title":"Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial","volume":"18","author":"Regine","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109864_bib20","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.surg.2025.109864_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ags3.12418","volume":"5","author":"Akita","year":"2021","journal-title":"Ann Gastroenterol Surg"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606025007160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606025007160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:21:25Z","timestamp":1780820485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606025007160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":20,"alternative-id":["S0039606025007160"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2025.109864","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of neoadjuvant gemcitabine and S-1 chemotherapy with or without concurrent radiation in patients with resectable and borderline resectable pancreatic cancer: A post hoc analysis of 2 phase II trials","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2025.109864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109864"}}